Scottish Medicines Consortium elvitegravir (Genvoya)

Scottish Medicines Consortium elvitegravir (Genvoya)

in the absence of a submission from the holder of the marketing authorisation:

elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide (Genvoya®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir in children aged from 6 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to toxicities.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Drug Name: elvitegravir (Genvoya)
SMC Drug ID: 1323/18
Manufacturer: Gilead Sciences Ltd
Indication: Treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir in children aged from 6 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to toxicities.
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 12 March 2018

To read more Press Release articles, click here.